Allez Health Announces $60 Million Capital Raise
2024年5月23日 - 1:30AM
ビジネスワイヤ(英語)
Biosensor venture secures Series A+ financing to invest in
operations, clinical development and commercialization
endeavors
Allez Health Inc., formerly known as Zense-Life Inc., an
emerging biosensor venture founded by proven experts in the
continuous glucose monitoring (CGM) space, announced a $60 million
Series A+ financing. The round was led by Korean in-vitro
diagnostics company, Osang Healthcare Co., Ltd. as a strategic
investor, with participation from existing investors. The new
capital is expected to be used to accelerate growth towards pivotal
trials, to support regulatory approval filings, and to scale
manufacturing operations.
Allez Health is a pioneering CGM biosensor platform with novel
sensor technology that is intended to disrupt today’s cost barrier
while enhancing performance and user experience. Since its
inception, Allez Health has accomplished several significant
milestones including seven issued patents and over 40 pending
patent applications, over 80 clinical studies aggregating more than
1,500 users, and a pivotal study in 120 insulin users. Having
completed the pivotal study and having secured key strategic
investment as well as select distribution and manufacturing
arrangements, Allez Health expects to accelerate its progress
toward commercialization in multiple global markets, assuming the
timely receipt of the necessary regulatory approvals and the
continued availability of capital.
“We believe that person-centric health is critical for optimal
health solutions,” says Leif Bowman, co-founder and CEO at Allez
Health. “We aim to bring to market a sensor that combines access,
affordability, and reliable performance, because when it comes to
an individual’s health, no one should have to choose between price
and performance.”
“Since the founding of Allez Health, we have been impressed by
their progress and are excited to officially forge a strong
collaboration with them,” says Dr. Chulhun Kang, CEO of Osang
Healthcare. “Their innovative design and technical advances,
coupled with Osang’s world-class manufacturing capability and
global reach, will bring meaningful access to world-class CGM
technology for millions of people with diabetes as well as the
broader wellness market.”
Allez Health, Inc. is an innovative smart biosensor company for
connected digital health platforms. The Allez Health sensor is an
investigational device that is not yet cleared or approved by the
U.S. Food and Drug Administration or any other regulatory
authority. For more information about Allez Health, visit
www.allezhealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522816000/en/
Allez Health Investor Contact: 619-631-5114
IR@allezhealth.com